Treat to target

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	6

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

trials per page:

Showing 1 to 6 of 6 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04324892 (ClinicalTrials.gov)	July 12, 2020	25/3/2020	Effects of Achieving SDAI Remission on Joint Space Outcomes Progression in Early Rheumatoid Arthriti ...	Effects of Achieving SDAI Remission on Joint Space Outcomes Progression in Early Rheumatoid Arthriti ...	Rheumatoid Arthritis	Drug: Treat to target	Chinese University of Hong Kong	NULL	Not yet recruiting	18 Years	N/A	All	110		NULL
2	EUCTR2016-002344-16-GB (EUCTR)	28/06/2018	29/11/2017	Targeted treatment early with etanercept and methotrexate or methotrexate with treat to target(stand ...	Targeted treatment early with etanercept (biosimilar) plus methotrexate or methotrexate with T2T car ...	Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Benepali Product Name: Benepali INN or Proposed INN: ETANERCEPT	University of Leeds	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	106	Phase 4	United Kingdom
3	EUCTR2012-004342-14-DK (EUCTR)	27/08/2013	19/04/2013	A Open-label Extension Study to Evaluate Long-term Safety and Efficacy With VX 509 in Subjects With ...	A Phase 2/3 Open-label Extension Study to Evaluate Long-term Safety and Efficacy With VX 509 in a Tr ...	Rheumatoid Arthritis MedDRA version: 14.1;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Product Name: VX-509 Product Code: VX-509 INN or Proposed INN: VX-509	Vertex Pharmaceuticals Incorporated	NULL	Not Recruiting			Female: yes Male: yes	40	Phase 2;Phase 3	United States;Estonia;Lithuania;Denmark;South Africa;Netherlands
4	EUCTR2012-004342-14-LT (EUCTR)	11/04/2013	29/01/2013	A Open-label Extension Study to Evaluate Long-term Safety and Efficacy With VX 509 in Subjects With ...	A Phase 2/3 Open-label Extension Study to Evaluate Long-term Safety and Efficacy With VX 509 in a Tr ...	Rheumatoid Arthritis MedDRA version: 16.1;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Product Name: VX-509 Product Code: VX-509 INN or Proposed INN: VX-509	Vertex Pharmaceuticals Incorporated	NULL	Not Recruiting			Female: yes Male: yes	40	Phase 2/3	United States;Estonia;Lithuania;Denmark;South Africa;Netherlands
5	NCT01830985 (ClinicalTrials.gov)	April 2013	10/4/2013	A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subj ...	A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in a Tr ...	Rheumatoid Arthritis	Drug: VX-509	Vertex Pharmaceuticals Incorporated	NULL	Completed	18 Years	65 Years	Both	39	Phase 2/Phase 3	United States;Estonia;Lithuania;South Africa
6	EUCTR2012-004342-14-EE (EUCTR)	26/02/2013	31/01/2013	A Open-label Extension Study to Evaluate Long-term Safety and Efficacy With VX 509 in Subjects With ...	A Phase 2/3 Open-label Extension Study to Evaluate Long-term Safety and Efficacy With VX 509 in a Tr ...	Rheumatoid Arthritis MedDRA version: 16.1;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Product Name: VX-509 Product Code: VX-509 INN or Proposed INN: VX-509	Vertex Pharmaceuticals Incorporated	NULL	Not Recruiting			Female: yes Male: yes	40	Phase 2/3	United States;Estonia;Lithuania;Denmark;South Africa;Netherlands

First Previous1Next Last